Sharon Mates, Intra-Cellular Therapies CEO
Intra-Cellular Therapies gets a boost on PhIII depression drug data
Biotech Intra-Cellular Therapies touting new data Tuesday for its drug designed to treat major depressive disorder.
The biotech shared results from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
